Iron deficiency anaemia and isolated iron deficiency are welldefined adverse prognostic factors in chronic heart failure in several North American and European studies. (Jankowska et al, 2010; Klip et al, 2013; Enjuanes et al, 2014) . Furthermore, recent meta-analysis of controlled trials giving intravenous iron to iron-deficient patients in chronic heart failure showed improved survival . In order to understand how these findings can be translated into practice for the management of patients with heart failure in Lower and Middle Income Countries (LMICs), it is necessary to consider the specific epidemiology of heart failure in these populations and how the syndrome of heart failure is related to iron deficiency and iron deficiency anaemia.
Epidemiology of heart failure
Heart failure is a global public health problem affecting an estimated 23 million people (Bui et al, 2011; Mozaffarian et al, 2015) . The diagnostic criteria for heart failure are based on a combination of symptoms and physical signs, as stated in the Framingham Heart Study criteria, which are 100% sensitive and with a specificity of 78% (McKee et al, 1971) . The definition of heart failure has been revised by the European Society of Cardiology (McMurray et al, 2012) and symptomatic heart failure is now graded using the New York Heart Association (NYHA) functional classification based on symptoms and signs (McMurray et al, 2012) .
The prevalence and incidence of heart failure are 3% and 0Á5% in HICs, increasing with age (McKee et al, 1971; Roger, 2013; Mozaffarian et al, 2015) . The detailed epidemiology of heart failure at the population level in sub-Saharan Africa is unknown, but hospital studies suggest that heart failure is the commonest cardiovascular condition and is responsible for >30% of admissions to cardiovascular units and between 3% and 7% of admissions to general internal medicine wards in Africa (Kengne et al, 2008) . Older studies have reported that heart failure accounts for about 15-20% of deaths among Africans admitted to hospitals (Abengowe, 1979; Couper & Walker, 1997) but the incidence and prevalence in populations is poorly defined.
The prevalence estimates for heart failure across Asia range from 1Á26% to 6Á7%. Rheumatic heart disease is a major contributor to heart failure in many parts of South Asia, such as India, but an increasing proportion of ischaemic heart disease is now evident in China and Japan (Sakata & Shimokawa, 2013) .
Aetiology
In the USA and Europe, the Acute Decompensated Heart Failure National Registry (ADHERE) and Euro Heart Failure Survey II (EHFS II) showed that ischaemic heart failure alone or in coexistence with hypertension, atrial fibrillation and diabetes constitute the commonest causes of heart failure, while a minority of patients suffer with dilated cardiomyopathy (McMurray & Stewart, 2000; Adams et al, 2005) .
Previous studies in sub-Saharan Africa have shown that the main aetiologies of heart failure were rheumatic heart disease and cardiomyopathies (Mayosi, 2007) and recent studies have shown that over 75% of cases of acute heart failure remain predominantly non-ischaemic, with hypertension, rheumatic heart disease and the endemic cardiomyopathies (i.e. idiopathic dilated cardiomyopathy, peri-partum cardiomyopathy and endomyocardial fibrosis) (Damasceno et al, 2012; Makubi et al, 2014) Nevertheless, ischaemic heart disease is increasingly recognised as a cause of heart failure, particularly in older age groups and in higher income groups and higher income countries, for example, affluent groups in Nigeria, Kenya and South Africa (Damasceno et al, 2012) .
In Latin America, the main aetiologies of heart failure are idiopathic dilated cardiomyopathy (1Á3-37%), Chagas Disease (1Á3-21%), ischaemic heart diseases (68-17%), systolic hypertension (14-76%), valvular heart disease (3-22%), and alcohol related (À1Á1-8%) .
Anaemia as an important comorbidity in heart failure
Given the poor prognosis and the difficultly of treating heart failure, even in Europe and North America, attention has been focused on understanding which comorbidities in the setting of heart failure are associated with poor outcome and how they may be treated and managed to ameliorate outcomes (Moe, 2016) It has recently been recognised that anaemia is not only a frequent and important co-factor in refractory heart failure (Mahfoud et al, 2009 ), but also is potentially amenable to intervention (Lund & Mancini, 2004) .
In studies from Europe and North America and other high income countries (HICs), anaemia is a common feature in heart failure, its prevalence increasing with worsening NYHA functional class, but variable in absolute proportion by the patient population and the haemoglobin level (Hb) used to define anaemia. There are many definitions for anaemia, but the widely-recognised guidelines from the World Health Organization (WHO) defines anaemia as Hb <130 g/l in men and <120 g/l in women (WHO, 2009 ) and further defined as mild (Hb 100-119 g/l for women and 100-129 g/l for men), moderate (Hb 70-99 g/l) or severe (Hb <70 g/l (World Health Organization, 2009; Kuule et al, 2009) .
The disparate definitions of anaemia explain, at least in part, why the reported prevalence of anaemia in heart failure ranges from 4% to 55% in various studies (Androne, 2003; Allen et al, 2009; McMurray et al, 2012) . In the Euro Heart Failure Survey II, which included 115 hospitals from 24 countries, 18% of male patients were anaemic (defined as a Hb <110 g/l), and here the prevalence of anaemia would have been 33% if the Hb threshold had been increased to 120 g/l (Cleland et al, 2003) These figures illustrate the sensitivity of the proportion of anaemic patients to a small change in the Hb threshold, as only a 10 g/l increase in the Hb threshold nearly doubled the proportion of anaemic patients.
The information on the presence of anaemia in LMICs in heart failure population is relatively limited using the WHO cut-off: the available information reveals that the prevalence of anaemia in heart failure in sub-Saharan Africa ranges from 14% to 64% (mean, 45%). In HIC the prevalence of iron deficiency in heart failure ranges from 14% to 73% depending on the study population and the diagnostic criteria applied (Table I) .
Corresponding data in LMICs such as those of subSaharan Africa are scarce, but it is not surprising that the estimates of iron deficiency in heart disease in Africa are high given that surveys in Tanzania estimated that 30-55% of the adult population is anaemic (Kitange et al, 1993; Tatala et al, 1998) and the prevalence iron deficiency anaemia was estimated to be 40-61% (Tatala et al, 1998; Massawe et al, 2002) .
A recent study in patients with heart failure from Tanzania (Tanzania Heart Failure (TaHeF) showed a prevalence of iron deficiency in heart failure at the upper end of these estimates and highlights the high prevalence of iron deficiency in non-anaemic patients (Makubi et al, 2014) . The study comprised 427 adults with heart failure defined by the Framingham criteria of McKee et al (1971) . The causes of heart failure were hypertension (45%), cardiomyopathy (28%), rheumatic heart disease (12%) and ischaemic heart disease (9%).
The prevalence of anaemia was 57% and iron deficiency was seen in 69% of anaemic subjects and in 21% of those without anaemia (Makubi et al, 2015) . Overall, 49% of the cohort was iron deficient, which emphasises the need for detailed assessment of iron status in those presenting with heart failure. The one-year survival-free hospitalisation for heart failure or death was 70%. The presence of iron deficiency anaemia increased the likelihood for hospitalisation for heart failure or death from any cause [Hazard ratio (HR) 2Á67, 95% confidence interval (CI) 1Á4-5Á1), while anaemia without iron deficiency did not influence the risk. Overall, the mortality rate was independently associated with presence of atrial fibrillation [hazard ratio (HR) 3Á4], anaemia (HR (Makubi et al, 2015) . These data show the very high prevalance of iron deficiency in African patients with heart failure and the adverse risk for severe clinical outcomes associated with iron deficiency.
Pathophysiology of anaemia in heart failure
The mechanisms of anaemia in heart failure are, surprisingly, not well known. It appears that the current well-described pathophysiological pathways that could account for anaemia, such as iron, folate or B 12 deficiency, renal failure or other comorbidities, including anaemia of chronic disease and dilutional anaemia (Horwich et al, 2002) , do not fully account for the clinical observations. Any form of anaemia may be a significant factor expected to exacerbate cardiac dysfunction, not only by reduced oxygen carrying capacity of the blood per unit volume, but also by increasing the work required to increase cardiac output to maintain delivery of sufficient oxygenated Hb to the tissues (Tang & Katz, 2006) There are many compensatory mechanisms that maintain oxygen delivery in anaemia, but some of these crucial pathways may be impaired by the pathology of some forms of heart disease where coronary artery stenosis and reduced vasodilation may limit blood supply and so oxygen delivery to the heart (De Boer et al, 2003) while there may be incidental anaemia, the cardio-renal syndrome, druginduced anaemia and iron deficiency have special significance for heart failure as they are linked to pathophysiology and/or therapy.
Cardio-renal syndrome
Chronic and progressive renal failure and associated anaemia is common in heart failure. The term 'cardio-renal syndrome' has been used, but a clear definition and well-defined pathophysiological pathway(s) do not exist. Renal failure in heart failure may be secondary to hypoperfusion and hypoxia, but also to venous congestion and inflammation and is likely to involve dysregulation of complex homeostatic pathways of perfusion, tissue oxygenation, fluid balance and myocardial function. Impaired nutrition, decreased bone marrow perfusion and side-effects from heart failure drugs may also contribute to both renal failure and anaemia (Anand, 2008; Usmanov et al, 2008) .
Use of angiotensin converting enzyme inhibitors
Angiotensin converting enzyme inhibitors may cause anaemia and are indeed used to treat erythrocytosis. They reduce the haematocrit following renal transplantation and may induce or contribute to anaemia in heart failure (Ishani et al, 2005) . 
Iron deficiency in heart failure

Iron deficiency
Two biochemical forms of iron deficiency are distinguished. The first is absolute deficiency, which is characterised by depletion of iron bound to transferrin in the circulation available for uptake by cells and intracellular iron stores, as hepatic ferritin and iron in macrophages. The causes of systemic iron deficiency by reduced intake, reduced absorption, chronic blood loss and/or to increased iron demand are well known (Lopez et al, 2016) . The second form of iron deficiency is functional iron deficiency, characterised by a reduction in transferrin-bound iron available in the circulation, although the body storage of iron is adequate. This is partly due to chronic inflammation, which is now recognised to play a part in heart failure. Increased erythrocyte sedimentation rate (ESR) and levels of the acute phase reactants Creactive protein (CRP) and ferritin are seen in heart failure (Torre-Amione et al, 1996; Horwich et al, 2002) and raised tumour necrosis factor-alpha and interleukin-6 concentrations are associated with the catabolic and dysmetabolic state seen late in the disease (Anker et al, 1997) . In some patients with anaemia and heart failure, iron can be absent in bone marrow stain, the gold standard for iron deficiency. However, in these patients, CRP is elevated and ferritin is not suppressed, as would be expected in iron deficiency, suggesting that inflammation does indeed play a role in anaemia. So it appears that ferritin may be elevated in chronic heart failure as an acute phase reactant in the face of true iron deficiency (Nanas et al, 2006; Schou et al, 2015) Such data may explain why iron supplementation is efficacious as an adjuvant treatment in heart failure, even in patient groups with ferritin concentration of up to 100 lg/l and up to 300 lg/l, with reduced transferrin saturations ( Table I) . The levels of hepcidin, the master regulator of iron, rise in inflammation (Nemeth & Ganz, 2006) . Hepcidin binds to the cellular iron export channel ferroportin, causing its internalisation and degradation, thereby decreasing iron efflux from iron exporting tissues into plasma. Hepcidin, therefore, inhibits dietary iron absorption, the efflux of recycled iron from splenic and hepatic macrophages, and the release of iron from storage in hepatocytes (Ganz, 2003; Nemeth & Ganz, 2006) . With either of the two forms of iron deficiency and regardless of the Hb, both oxygen delivery and utilisation are impaired in myocardial and other cells (Haas & Brownlie, 2001; Brownlie et al, 2002) .
Pathophysiology of iron deficiency in the failing heart
Iron is essential for multiple pathways central to cell growth, transport of oxygen, oxidative phosphorylation and for the function of dozens of enzymes (Nemeth & Ganz, 2006) . However, iron deficiency has been considered clinically important only in the presence of anaemia. It is crucial to understand that iron deficiency impairs aerobic performance regardless of the presence of anaemia (Anker et al, 2009) , suggesting that iron deficiency without anaemia could be relevant to reduced muscle function in a failing heart.
The effect of reduced iron availability on cardiac and skeletal muscle cells may be to impair oxygen storage through reduced myoglobin and to directly reduce energy generation by mitochondria and, thereby, the efficiency of the heart and skeletal muscle to maintain contractile strength and endurance (Jankowska et al, 2010; Frise et al, 2016; Stugiewicz et al, 2016) . The effects of iron deficiency on patients with cardiac disease therefore go far beyond any reduction in oxygen supply but may contribute to directly to worsening cardiac or skeletal muscle function (Von Haehling et al, 2015) .
Finally, iron deficiency has been associated with electrocardiographic abnormalities, including increased incidence of atrial fibrillation and p wave dispersion, independent of heart failure (Simsek et al, 2010) Indeed, iron deficiency is associated with more widespread abnormal autonomic dysfunction and with high resting heart rate and reduced heart rate variability due to reduced parasympathetic tone (Yokusoglu et al, 2007; Jarjour & Jarjour, 2013) ).
Low myocardial iron can be determined directly, at least semi-quantitatively. Cardiac magnetic resonance imaging studies show that low myocardial iron (as measured by myocardial T2* imaging) was associated with non-ischaemic heart failure (Nagao et al, 2014 (Nagao et al, , 2015 While there may be multiple pathways through which iron deficiency can impair cardiac function, tissue Doppler and strain rate measurements show significant improvements in diastolic and systolic myocardial function in iron-deficient patients after iron replacement therapy (Gaber et al, 2012) .
Diagnosis of iron deficiency in heart failure
Various studies have suggested higher levels (60-100 lg/l) of serum ferritin as necessary and sufficient for diagnosing absolute iron deficiency in the presence of coexisting inflammation, infection and malignancy, as opposed to the more commonly used serum ferritin cut-off level of <30 lg/l (Guyatt et al, 1990). Even stricter cut-off values, 12-15 lg/l, have been used in the absence of inflammation (Alt et al, 1978) . These elevated levels of ferritin for diagnosis of functional iron deficiency with acute or chronic inflammatory response, simply reflect the fact that serum ferritin is an acute phase reactant.
Therefore, in heart failure, iron deficiency has been defined in two forms; (i) absolute iron deficiency which is defined as serum ferritin <100 lg/l and (ii) functional iron deficiency defined as serum ferritin 100-300 lg/l and transferrin saturation <20% (Nanas et al, 2006) . These criteria have been used in several clinical trials in heart failure (Okonko et al, 2008; Anker et al, 2009; Ponikowski et al, 2014) . The current European Guidelines for the diagnosis and management of heart failure (McMurray et al, 2012) , reflect the need to test for anaemia and evaluate iron status. The guidelines recommend a complete blood count, serum ferritin, iron and transferrin saturation in all patients and then further tests as needed to establish a diagnosis of anaemia if the Hb <130 g/l (men) or 120 g/l (women) (McMurray et al, 2012) .
It is unclear how these diagnostic criteria for iron deficiency and functional iron deficiency should be applied in LMICs, where diagnosis of functional iron deficiency is confounded by the existence of relatively high frequency of chronic infections and haemglobinopathies (Makani & Roberts, 2016; Pasricha & Drakesmith, 2016) . There is the additional problem of availability of measurements of serum ferritin and transferrin saturation, which are only measured in larger regional or national centres in many African countries.
A possible approach would be to develop simplified criteria for the diagnosis of functional iron deficiency using the full blood count and measures of systemic inflammation such as ESR or CRP. Moreover, a simplified and safe scheme of oral iron supplementation may allow sensitive but less specific diagnostic criteria to be applied for the identification of heart failure patients who would benefit from oral iron therapy.
Prognostic role of iron deficiency in heart failure
There is increasing evidence that iron deficiency anaemia and iron deficiency in the absence of anaemia are associated with a worse prognosis in heart failure (Klip et al, 2013; Enjuanes et al, 2014; Jankowska et al, 2014; Rangel & De Sousa, 2014; Makubi et al, 2016) . Pooled analyses showed that iron deficiency was associated with reduced quality of life (Com ın-Colet et al, 2013) and carried a higher risk of poor outcome in heart failure irrespective of the presence of anaemia (Klip et al, 2013) .
Intervention studies for iron deficiency in heart failure
Recombinant human erythropoietin
Several agents have been explored as potential therapies for anaemia and iron deficiency in heart failure. Erythropoiesisstimulating agents such as recombinant human erythropoietin raise Hb and improve functional and exercise capacity and quality of life in heart failure (Mancini et al, 2003) , and in the Study of Anaemia in Heart Failure Trial (STAMINAHeFT) it was associated with a trend toward lower combined all-cause mortality and heart failure hospitalisation (Ghali, 2009) . However, these agents may be associated with adverse thromboembolic outcomes (McMurray et al, 2009; Sandhu et al, 2010) and these adverse events have focused attention on the use of iron supplementation as an adjuvant therapy in heart failure.
Iron supplementation
A series of well-designed and high-profile randomised clinical trials have shown the clinical benefit of iron therapy, not just in those patients with heart failure who show biochemical and haematological evidence of classical iron deficiency, but in a wide spectrum of patients with ferritin levels of up to 100 lg/l or up to 300 lg/l with reduced transferrin saturation (<20%) ( Table I ). The relatively recent availability of iron-carboxymaltose or iron-sucrose parental iron preparations with relatively low toxicity (compared with the older iron-dextran preparation) and the ability to give substantial and therapeutic iron supplementation in one or two doses has led to enormous interest in the therapeutic use of such preparations to a wide spectrum of patients (McDonagh & Macdougall, 2015) .
Parenteral iron therapy conferred short-to medium-term benefits in the form of improved symptoms, quality of life measures and reduced hospitalisation rates in a number of controlled and uncontrolled clinical trials in heart failure and iron deficiency (Bolger et al, 2006; Okonko et al, 2008; Usmanov et al, 2008; Anker et al, 2009; Ponikowski et al, 2014; Reed et al, 2015) (Table II) , all conducted in developed countries. In the Ferinject Assessment in Patients with Iron Deficiency and Chronic Heart Failure (FAIR-HF) study, patients were randomised to intravenous iron or placebo: 50% vs. 28% and 47% vs. 30% reported improved quality of life and improved NYHA class, respectively (Anker et al, 2009) . Similarly, in the Ferric Iron Sucrose in Heart Failure (FERRIC-HF) study, 35 patients with heart failure were subjected to 16 weeks of intravenous iron or no treatment in a 2:1 ratio. The NYHA functional class improved in eight patients (44%) in the iron group versus none of the patients in the control group (P = 0Á03) (Okonko et al, 2008) . These two large-scale trials have been supported by several more recent studies. By combining the results of these studies in systematic reviews and meta-analyses, it is now possible to examine the effect of parenteral iron on a range of clinically significant outcomes.
Intravenous iron therapy reduces the risk of the combined endpoint of death from all causes or hospital admission for heart disease [odds ratio (OR) 0Á44, 95% CI 0Á30-0Á64, P < 0Á0001], and the combined endpoint of death from heart disease or hospitalisation for worsening heart failure (OR 0Á39, 95% CI 0Á24-0Á63, P = 0Á0001) Qian et al, 2016) . These highly medically and statistically significant results are accompanied by significant improvement in a range of morbidity scores and, perhaps not so surprisingly, haematological parameters. Intravenous iron therapy resulted in a reduction in NYHA class (a mean net effect) (À0Á54 class, 95% CI À0Á87 to À0Á21, P = 0Á001) and an increase in 6-minute walking test distance (+31 m, 95% CI 18-43, P < 0Á0001. It is notable that these results have been achieved without adverse events (Qian et al, 2016) The use of intravenous iron is now incorporated into European guidelines on the management of heart disease (McMurray et al, 2012) but intravenous iron for heart failure has not been studied in sub-Saharan Africa, where it seems more likely that other forms of iron replacement would have to be used for economic and operational reasons.
Interventions for iron deficiency anaemia in heart failure in LMICs
There are few intervention studies for iron deficiency anaemia in heart failure in LMICs (Table II) . In particular, there are few studies that compare the effect of prohibitively expensive and complex intravenous iron therapy in heart failure compared with cheap and easily available oral iron supplementation. Oral iron is an established therapy for treating iron deficiency in a wide range of medical conditions but has not yet been widely tested in heart failure. Preliminary studies on a randomised clinical trial on erythropoietinstimulating agents vs. oral iron showed no iron improvement with oral therapy on Hb, exercise and ferritin. However, in Brazil, a randomised trial (Beck-da-Silva et al, 2013) showed that ferritin and Hb increased with both intravenous and oral iron. Moreover, in a recent, non-randomised clinical trial (Niehaus et al, 2015) oral iron showed improvements in Hb, transferrin saturation and ferritin that were similar to those seen with intravenous iron in the FAIR trial in patients with heart failure and preserved left ventricular ejection fraction (Anker et al, 2009 ). In Africa, recent studies have begun to explore the role of oral iron in heart failure.
In a Tanzanian prospective, single-arm clinical trial in patients aged >18 years with stable symptomatic (NYHA II-IV) heart failure, Hb >80 g/l, and iron deficiency, defined as serum ferritin level <100 lg/l or 100-299 lg/l with concurrent transferrin saturation <20%, oral ferrous sulphate (200 mg tds) was given for 90 days (Makubi et al, 2016) . In 97 out of 102 patients who started the study and who completed follow-up, the ferritin level improved from 123 AE 70 (mean AE SD) lg/l at baseline to 255 AE 143 lg/l after 90 days of treatment (P < 0Á001), Hb from 117 AE 20 to 123 AE 20 g/l (P < 0Á001), 6-minute walking distance from 543 AE 148 to 574 AE 166 m (absolute increase of 29 m; P < 0Á001) and left ventricular ejection fraction from 37Á8 AE 12Á2 to 44Á5 AE 10Á7% (+17%; P < 0Á001). Further biochemical evidence of improved cardiac function comes from a reduction in N-terminal pro B-type natriuretic peptide from 986 AE 774 to 582 AE 503 pg/ml (À41%; P < 0Á001) (Makubi et al, 2016) . These results show comparable results to those seen with parenteral iron and suggest that treatment with readily-available oral iron may be efficacious for patients with heart failure and iron deficiency in Africa.
Conclusion
Heart failure continues to remain a substantial burden on the healthcare systems and communities in both developed and sub-Saharan African countries. Although a lot of progress has been made with regard to our understanding of the natural history of heart failure in developed countries, the picture is more complex in sub-Saharan Africa where there are limited studies available to fully chart and understand the different aetiologies and comorbidities and so, pathways of effective treatment. The data show up to 60% of patients presenting with heart failure have absolute or functional iron deficiency. Anaemia and iron deficiency, in isolation or in combination, are important comorbidities in heart failure and confer poor prognosis. Its treatment has been shown to improve the outcome in heart failure patients in developed countries. In sub-Saharan Africa, the relationship between anaemia and iron deficiency remains largely unexplored and more information is needed to tackle this increasing public health problem for further development of locally feasible and acceptable interventions.
